IQVIA Blog Post on RWE Considerations in Drug Development Pipeline

June 1, 2021

Real world evidence (RWE) experts at IQVIA shared their thoughts on when it’s appropriate to use RWE during the drug development pipeline. They note that it can be incorporated into both pre-launch and post-launch settings. The authors also discuss criteria that should be used to assess whether or not RWE can be effectively used in clinical trials. Some of the key benefits of RWE include reduced costs and increased study efficiency, making this an important tool for a variety of stakeholders.

“In many cases, regulators will consider RWE to support accelerated reviews and early authorization if a treatment addresses an unmet medical need in a serious condition. In these cases, the data must prove that an unmet medical need will be fulfilled, and the benefits of the medicinal product’s immediate availability to public health will outweigh risks related to the need for further data.” Read more here.

(Source: IQVIA, 7/30/20)

Share This Story!